Washington, D.C. 20549
Pursuant to Section 13 or 15(d) of
the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): August 28, 2019
Medtronic Public Limited Company
(Exact name of Registrant as Specified in its Charter)
(State or other jurisdiction
of incorporation)
File Number)
(IRS Employer
Identification No.)
20 On Hatch, Lower Hatch Street
Dublin 2, Ireland
(Address of principal executive offices)
+353 1 438-1700
(Registrant's telephone number; including area code):
Not Applicable
Former name or former address, if changed since last report
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:
Title of each class
Trading Symbol
Name of each exchange on which registered
Ordinary shares, par value $0.0001 per share
New York Stock Exchange
Floating Rate Notes due 2021
New York Stock Exchange
0% Senior Notes due 2021
New York Stock Exchange
0.00% Senior Notes due 2022
New York Stock Exchange
0.375% Senior Notes due 2023
New York Stock Exchange
0.25% Senior Notes due 2025
New York Stock Exchange
1.125% Senior Notes due 2027
New York Stock Exchange
1.625% Senior Notes due 2031
New York Stock Exchange
1.00% Senior Notes due 2031
New York Stock Exchange
2.250% Senior Notes due 2039
New York Stock Exchange
1.50% Senior Notes due 2039
New York Stock Exchange
1.75% Senior Notes due 2049
New York Stock Exchange

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company o

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. o

Item 5.02.

On August 23, 2019, the Board of Directors (the “Board”) of Medtronic plc (the “Company” or “Medtronic”) approved the appointment of Geoffrey S. Martha as the Company’s new President, and related personnel changes, as well as the increase in the number of members of the Board from eleven (11) to twelve (12) and the appointment of Mr. Martha as a director of the Company, all effective November 1, 2019. Mr. Martha will report to Chairman and Chief Executive Officer Omar Ishrak. Effective April 26, 2020, Mr. Ishrak will retire as Chief Executive Officer of the Company and will become Executive Chairman of the Company. On April 27, 2020, Mr. Martha will become Chief Executive Officer of the Company. These changes are part of the Board’s leadership succession planning process and are aligned with the Company’s mandatory retirement policy for executive officers.
Mr. Martha, age 49, has been Company’s Executive Vice President and President, Restorative Therapies Group since June 2015. Mr. Martha previously served as Senior Vice President of Strategy and Business Development of the Company beginning in January 2015 and of Medtronic, Inc. beginning in August 2011. Prior to that, he served as Managing Director of Business Development at GE Healthcare from April 2007 to July 2011; General Manager for GE Capital Technology Finance Services from November 2003 to March 2007; Senior Vice President, Business Development for GE Capital Vendor Financial Services from February 2002 to October 2003; General Manager for GE Capital Colonial Pacific Leasing from February 2001 to January 2002; and Vice President, Business Development for Potomac Federal, the GE Capital federal financing investment bank from May 1998 to January 2001.
In connection with Mr. Martha’s appointment as President, the Company and Mr. Martha entered into a Letter Agreement, dated August 26, 2019, which sets forth certain terms of his employment as President. Effective upon becoming President (and continuing after he becomes Chief Executive Officer), Mr. Martha will receive an annualized base salary of $1,100,000 and be eligible for a target annual bonus opportunity of 150% of his base salary, each prorated in the year of appointment. In addition, upon appointment, Mr. Martha will receive a one-time equity grant under the Medtronic plc Amended and Restated 2013 Stock Award and Incentive Plan. The grant date value of the equity award will be $3.1 million. The equity grant will be apportioned among stock options (1/3); restricted stock units (1/3); and a three-year cash incentive plan called the Long-Term Performance Plan (“LTPP”) (1/3). No additional compensation will be provided to Mr. Martha for his service as a director on the Board.
The stock options will have a ten-year term and vest over four years in equal increments of 25% per year beginning July 29, 2020. The restricted stock units (“RSUs”) will cliff vest (100%) on July 29, 2022, subject to a three-year minimum performance threshold that must be met before the RSUs vest. For fiscal year 2020 RSU grants, the performance threshold was set as the cumulative diluted EPS over a three-year period based on a compound annual growth rate of 3%. The LTPP will pay in cash after the end of the three fiscal year performance period (fiscal years 2020-2022), based on achievement of the LTPP’s performance goals.
Mr. Martha will also be entitled to a business allowance, personal aircraft usage and participation in the Company's severance and change in control plans consistent with current Executive Officer levels.
The Company and Mr. Ishrak also entered into a Letter Agreement, dated August 23, 2019, pursuant to which Mr. Ishrak’s base salary will decrease on April 27, 2020 to $1,000,000 annually, prorated in the year his appointment to Executive Chairman becomes effective and following his retirement as Chief Executive Officer. The terms of his employment otherwise continue in full force and effect.
A copy of the Company’s press release, dated August 28, 2019, is filed as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.

Item 9.01.
(d) List of Exhibits
Exhibit Number

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Date: August 28, 2019
/s/ Bradley E. Lerman
Bradley E. Lerman

Senior Vice President, General Counsel and Corporate Secretary


Exhibit Number


Exhibit 99.1
Rob Clark

Ryan Weispfenning
Public Relations

Investor Relations




Omar Ishrak Will Retire as CEO at End of Fiscal Year;
Remains Chairman of the Board and Becomes Executive Chairman of Medtronic

Geoff Martha, EVP of the Restorative Therapies Group, Appointed Medtronic President, and Will Join the Medtronic Board of Directors, Effective November 1, 2019
Martha Succeeds Ishrak as CEO, Effective April 27, 2020

Brett Wall, President of RTG’s Brain Therapies Division, Appointed EVP of RTG

DUBLIN - August 28, 2019 - Medtronic plc (NYSE:MDT) today announced that Omar Ishrak, Medtronic’s Chairman and Chief Executive Officer (CEO), has announced his intention to retire as CEO on April 26, 2020, following the end of the company’s current fiscal year. As a result, the Medtronic Board of Directors announced key leadership appointments as part of its multi-year, leadership succession planning process, which will ensure a smooth and successful transition in leadership across the company.

The Board of Directors has unanimously appointed Geoff Martha, currently Executive Vice President (EVP) of the company’s Restorative Therapies Group (RTG), to assume the newly created role of Medtronic President and become a member of the Medtronic Board of Directors, effective November 1, 2019. Martha will succeed Ishrak as Medtronic CEO, effective April 27, 2020. As President, Martha will lead Medtronic’s operating groups and regions. Brett Wall, President of Medtronic’s Brain Therapies division, was appointed EVP and Group President of RTG, succeeding Martha, effective November 1, 2019.


At the start of Medtronic’s next fiscal year, on April 27, 2020, Ishrak will assume a new position of Executive Chairman, which will provide counsel and guidance to Medtronic’s leadership, oversee CEO succession, and drive the ongoing successful execution of Medtronic’s long-term strategic plan. These changes are designed to ensure a smooth transition, continuity of leadership and a continued focus on delivering Medtronic’s innovation strategy and financial performance.

“Today, we announced leadership changes that meet both the Board’s objective of executing a thoughtful leadership transition as well as my personal desire to begin transitioning my duties as CEO to a new leader coinciding with the start of our next fiscal year,” said Ishrak. “This plan and its timing enable Geoff and I to partner on achieving Medtronic’s key financial performance goals as well as delivering on our critical pipeline milestones, including several important product launches. Leading Medtronic as CEO is an honor and a privilege, and I know that Geoff is the right leader to take Medtronic to the next level of its growth and evolution. Geoff is a results-oriented, dynamic, and innovative business leader who is passionately committed to our Mission, the advancement of our growth strategy and the development and diversity of our people. I am confident he has the right track record, commitment, vision and judgment to lead our company.”

“As Omar approaches the company’s mandatory executive officer retirement of 65 years of age next year, we have ensured Medtronic has the right leadership at the right time to advance its Mission and deliver shareholder return through a seamless transition,” said Scott Donnelly, Medtronic’s Lead Director, and Chairman, President and CEO of Textron, Inc. “The Board is extremely grateful to Omar for his outstanding leadership - as the company’s annual revenues have doubled and its market capitalization has increased by more than $100 billion during his tenure. We are confident Omar’s contributions to Medtronic will continue as Executive Chairman. The Board’s succession planning process prioritizes developing leaders from within the company, and we are pleased that we could advance Geoff and Brett for these roles. During his time at Medtronic, Geoff has demonstrated his unique ability to lead, innovate and drive results, and the Board has full confidence in him and his ability to take Medtronic into its next chapter of growth.”

“I’m humbled and grateful for the opportunity to lead such an amazing company,” said Martha. “Since coming to Medtronic, I have been deeply motivated and inspired by the company’s Mission, its people and its unique ability to create and commercialize technology that directly improves and saves people’s lives. I thank Omar and the entire Board for their vote of confidence in selecting me as President and as the company’s next CEO. I know that with the support and dedication of my Medtronic colleagues around the


globe, we can continue to deliver new levels of performance for patients, customers and healthcare systems we serve - and for our shareholders and business partners.”

More on Geoff Martha
Martha joined Medtronic in 2011 and became EVP and President of Medtronic’s Restorative Therapies Group, with more than $8 billion in annual revenues and more than 14,000 employees, in 2015. Martha has responsibility for RTG’s four divisions which include Brain Therapies, Pain Therapies, Specialty Therapies and Spine. The division’s products and therapies include spinal and orthopedic implants, surgical navigation systems, robotic surgery systems, deep brain stimulation systems, drug infusion systems and stimulators to reduce chronic pain, and interventional devices to treat ischemic stroke.

Under his leadership, Martha directed the reorganization of RTG around key therapy areas and returned the Group to meaningful, consistent growth through innovation, including the introduction of new products, leveraging the Group’s products and services into integrated portfolios and executing impactful acquisitions and partnerships. During his time as President of RTG, Martha has revitalized its businesses, turning in a record performance in fiscal year 2019 with more than $8 billion in revenues, growing RTG at six percent. In fiscal year 2019, RTG posted quarterly revenues averaging more than $2 billion per quarter - the most in its history.

Prior to his current role, Martha was head of Medtronic Corporate Strategy and Business Development, where he led the company’s 2014 acquisition of Covidien, the largest acquisition in the history of the medical technology industry. In July 2014, he was named the Chief Integration Officer for the integration of Covidien into Medtronic and was named President of RTG in 2015. Prior to Medtronic, Martha spent 19 years in a variety of business development, strategic marketing, and sales management roles at GE Healthcare and GE Capital.

Martha has been an active champion for the advancement of women and ethnically diverse representation at Medtronic as well as proactive engagement in the communities where Medtronic employees live and work. He is the executive sponsor of Medtronic’s African Descent Network, which is focused on the recruitment, engagement, retention and development for Medtronic employees of African descent. He also serves as Medtronic’s executive sponsor of FIRST Robotics and sits on the board of Children’s HeartLink and the Northside Achievement Zone, a community collaborative that works to end generational poverty in North Minneapolis.


Brett Wall to Lead Medtronic’s Restorative Therapies Group
Brett Wall, currently senior vice president and president of RTG’s Brain Therapies division, will assume the position of EVP and Group President of RTG in November 2019. Wall has more than 25 years of experience in the medical technology industry and joined Medtronic in 2015 as part of the Covidien acquisition. Under his leadership, the Brain Therapies division has produced double digit annual growth rates and brought to market innovative stroke and brain therapies, including the Solitaire™ Revascularization device that revolutionized the minimally invasive treatment for ischemic stroke.

At Covidien, Wall served as President, Neurovascular and International, where he managed all commercial activities and functions of the business. Wall’s previous positions include senior sales, marketing and operational leadership positions with ev3, Boston Scientific and C.R. Bard. Wall has an extensive global background, leading businesses and operations in Europe and the Asia Pacific region.

“It is truly an honor to be selected by the Board to lead the Restorative Therapies Group, a group that Geoff has so successfully led over the past four years,” said Wall. “It’s my absolute privilege to lead this Group, which has an incredibly strong leadership team and more than 14,000 dedicated and passionate team members around the world. RTG is at the forefront of our company’s innovation agenda, and I look forward to continuing and building upon our Group’s track record of driving patient impact and shareholder return.”

About Medtronic
Medtronic plc (, headquartered in Dublin, Ireland, is among the world's largest medical technology, services and solutions companies - alleviating pain, restoring health and extending life for millions of people around the world. Medtronic employs more than 90,000 people worldwide, serving physicians, hospitals and patients in more than 150 countries. The company is focused on collaborating with stakeholders around the world to take health care Further, Together.

Any forward-looking statements are subject to risks and uncertainties such as those described in Medtronic's periodic reports on file with the Securities and Exchange Commission. Actual results may differ materially from anticipated results.